Clinical trials have demonstrated the ability of these vectors to induce high frequencies of CD8+ T cells associated with the induction of useful levels of efficacy in the controlled human malaria infection (CHMI) model [1] and a field trial in a malaria-endemic population [2]. This evidence concerns the gene CD8A and malaria.